161 related articles for article (PubMed ID: 23893155)
1. Castration-resistant prostate cancer: a strategy to enhance response to androgen deprivation.
Stanevsky Y; Tsivian A; Tsivian M
Asian J Androl; 2013 Nov; 15(6):709-10. PubMed ID: 23893155
[TBL] [Abstract][Full Text] [Related]
2. The genetics of castration-resistant prostate cancer: what can the germline tell us?
Sharifi N; Dahut WL; Figg WD
Clin Cancer Res; 2008 Aug; 14(15):4691-3. PubMed ID: 18676736
[TBL] [Abstract][Full Text] [Related]
3. Stem cells in prostate cancer: resolving the castrate-resistant conundrum and implications for hormonal therapy.
Sharifi N; Kawasaki BT; Hurt EM; Farrar WL
Cancer Biol Ther; 2006 Aug; 5(8):901-6. PubMed ID: 16855379
[TBL] [Abstract][Full Text] [Related]
4. A co-clinical approach identifies mechanisms and potential therapies for androgen deprivation resistance in prostate cancer.
Lunardi A; Ala U; Epping MT; Salmena L; Clohessy JG; Webster KA; Wang G; Mazzucchelli R; Bianconi M; Stack EC; Lis R; Patnaik A; Cantley LC; Bubley G; Cordon-Cardo C; Gerald WL; Montironi R; Signoretti S; Loda M; Nardella C; Pandolfi PP
Nat Genet; 2013 Jul; 45(7):747-55. PubMed ID: 23727860
[TBL] [Abstract][Full Text] [Related]
5. Stimulation of cellular senescent processes, including secretory phenotypes and anti-oxidant responses, after androgen deprivation therapy in human prostate cancer.
Kawata H; Kamiakito T; Nakaya T; Komatsubara M; Komatsu K; Morita T; Nagao Y; Tanaka A
J Steroid Biochem Mol Biol; 2017 Jan; 165(Pt B):219-227. PubMed ID: 27329245
[TBL] [Abstract][Full Text] [Related]
6. Genetics: ZBTB7A suppresses castration-resistant prostate cancer.
Razzak M
Nat Rev Clin Oncol; 2013 Aug; 10(8):427. PubMed ID: 23774644
[No Abstract] [Full Text] [Related]
7. Biologic agents as adjunctive therapy for prostate cancer: a rationale for use with androgen deprivation.
Nelson EC; Cambio AJ; Yang JC; Lara PN; Evans CP
Nat Clin Pract Urol; 2007 Feb; 4(2):82-94. PubMed ID: 17287869
[TBL] [Abstract][Full Text] [Related]
8. Testosterone in prostate cancer: the Bethesda consensus.
Djavan B; Eastham J; Gomella L; Tombal B; Taneja S; Dianat SS; Kazzazi A; Shore N; Abrahamsson PA; Cheetham P; Moul J; Lepor H; Crawford ED
BJU Int; 2012 Aug; 110(3):344-52. PubMed ID: 22129242
[TBL] [Abstract][Full Text] [Related]
9. Obesity is associated with castration-resistant disease and metastasis in men treated with androgen deprivation therapy after radical prostatectomy: results from the SEARCH database.
Keto CJ; Aronson WJ; Terris MK; Presti JC; Kane CJ; Amling CL; Freedland SJ
BJU Int; 2012 Aug; 110(4):492-8. PubMed ID: 22094083
[TBL] [Abstract][Full Text] [Related]
10. Pharmacological inhibition of the Notch pathway enhances the efficacy of androgen deprivation therapy for prostate cancer.
Cui J; Wang Y; Dong B; Qin L; Wang C; Zhou P; Wang X; Xu H; Xue W; Fang YX; Gao WQ
Int J Cancer; 2018 Aug; 143(3):645-656. PubMed ID: 29488214
[TBL] [Abstract][Full Text] [Related]
11. Androgen deprivation therapy in patients with localized disease: Comparison with curative intent treatments and time to castration resistance. Results of the Spanish Prostate Cancer Registry.
Garcia-Rodriguez J; Fernandez-Gomez JM; Cozar JM; Miñana B; Gomez-Veiga F; Rodriguez-Antolin A; ;
Actas Urol Esp (Engl Ed); 2020 Apr; 44(3):156-163. PubMed ID: 32113829
[TBL] [Abstract][Full Text] [Related]
12. Androgen receptors in hormone-dependent and castration-resistant prostate cancer.
Shafi AA; Yen AE; Weigel NL
Pharmacol Ther; 2013 Dec; 140(3):223-38. PubMed ID: 23859952
[TBL] [Abstract][Full Text] [Related]
13. [Metastatic hormone-sensitive prostate cancer: more than just androgen-deprivation therapy].
Mechahougui H; Achard V; Friedlaender A
Rev Med Suisse; 2020 May; 16(695):1098-1101. PubMed ID: 32462838
[TBL] [Abstract][Full Text] [Related]
14. Abiraterone and novel antiandrogens: overcoming castration resistance in prostate cancer.
Ferraldeschi R; Pezaro C; Karavasilis V; de Bono J
Annu Rev Med; 2013; 64():1-13. PubMed ID: 23020876
[TBL] [Abstract][Full Text] [Related]
15. Prostate cancer progression after androgen deprivation therapy: mechanisms of castrate resistance and novel therapeutic approaches.
Karantanos T; Corn PG; Thompson TC
Oncogene; 2013 Dec; 32(49):5501-11. PubMed ID: 23752182
[TBL] [Abstract][Full Text] [Related]
16. Reconsideration of progression to CRPC during androgen deprivation therapy.
Mizokami A; Namiki M
J Steroid Biochem Mol Biol; 2015 Jan; 145():164-71. PubMed ID: 24717975
[TBL] [Abstract][Full Text] [Related]
17. Androgen deprivation therapy for advanced prostate cancer: why does it fail and can its effects be prolonged?
Singer EA; Golijanin DJ; Messing EM
Can J Urol; 2008 Dec; 15(6):4381-7. PubMed ID: 19046491
[TBL] [Abstract][Full Text] [Related]
18. Intra-prostatic androgen levels during various androgen-blockade regimens.
Nishiyama T
Best Pract Res Clin Endocrinol Metab; 2008 Apr; 22(2):229-41. PubMed ID: 18471782
[TBL] [Abstract][Full Text] [Related]
19. Emerging therapies in castrate-resistant prostate cancer.
Zarour L; Alumkal J
Curr Urol Rep; 2010 May; 11(3):152-8. PubMed ID: 20425621
[TBL] [Abstract][Full Text] [Related]
20. Polymorphisms in androgen metabolism genes with serum testosterone levels and prognosis in androgen-deprivation therapy.
Shiota M; Endo S; Fujimoto N; Tsukahara S; Ushijima M; Kashiwagi E; Takeuchi A; Inokuchi J; Uchiumi T; Eto M
Urol Oncol; 2020 Nov; 38(11):849.e11-849.e18. PubMed ID: 32712140
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]